Clinical Outcomes of Arthroscopic Rotator Cuff Repair Using Poly Lactic-co-glycolic Acid Plus β-tricalcium Phosphate Biocomposite Suture Anchors
10.5397/cise.2018.21.1.22
- Author:
Seok Won CHUNG
1
;
Kyung Soo OH
;
Sung Jin KANG
;
Jong Pil YOON
;
Joon Yub KIM
Author Information
1. Department of Orthopaedic Surgery, Konkuk University School of Medicine, Seoul, Korea. smilecsw@gmail.com
- Publication Type:Original Article
- Keywords:
Biocomposite suture anchor;
Fixone;
Healix;
Rotator cuff repair;
Outcomes
- MeSH:
Absorption;
Elbow;
Follow-Up Studies;
Humans;
Incidence;
Magnetic Resonance Imaging;
Rotator Cuff;
Shoulder;
Surgeons;
Suture Anchors;
Sutures;
Tears
- From:Clinics in Shoulder and Elbow
2018;21(1):22-29
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: This study is performed to evaluate anchor-related outcomes and complications after arthroscopic rotator cuff repair using 30% β-tricalcium phosphate (β-TCP) with 70% poly lactic-co-glycolic acid (PLGA) biocomposite suture anchors. METHODS: A total of 78 patients (mean age, 61.3 ± 6.9 years) who underwent arthroscopic medium-to-large full-thickness rotator cuff tear repair were enrolled. The technique employed 30% β-TCP with 70% PLGA biocomposite suture anchors at the medial row (38 patients, Healix BRTM anchor [Healix group]; 40 patients, Fixone anchor B [Fixone group]). The radiologic outcomes (including perianchor cyst formation or bone substitution) and anatomical outcomes of the healing failure rate were evaluated using magnetic resonance imaging at least 6 months after surgery, the pain visual analogue scale at 3, 6 months, and final follow-up visit, and American Shoulder and Elbow Surgeons scores at least 1 year postoperatively. Anchor-related complications were also evaluated. RESULTS: The perianchor cyst formation incidence was similar for both groups (60.5%, Healix group; 60.0%, Fixone group; p=0.967), although severe perianchor cyst incidence was slightly lower in the Fixone group (15.0%) than in the Healix group (21.1%). There was no occurrence of anchor absorption and bone substitution. No differences were observed in the healing failure rate (13.2%, Healix group; 15.0%, Fixone group; p=0.815) and functional outcome between groups (all p>0.05). Anchor breakage occurred in 5 patients (2 Healix anchors and 3 Fixone anchors); however, there were no major anchor-related complications in either group. CONCLUSIONS: No differences were observed in the clinical outcomes of the Healix and Fixone groups, neither were there any accompanying major anchor-related complications.
